Comments
Natco Pharma has launched a fixed dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C under the brand name Hepcinat Plus in India.
The product is a generic fixed dose combination of Sofosbuvir 400 mg and Daclatasvir 60mg tablets used for the treatment of patients with chronic Hepatitis C virus infection, the company said in a filing to the BSE.
Natco Pharma has launched the drug at a maximum retail price of Rs 17,500 for a bottle of 28 tablets. Shares of Natco Pharma were trading down by 2.01 per cent at Rs 787.35 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.